CN112920242B - Benzimidazole derivative BI292 and preparation method and application thereof - Google Patents
Benzimidazole derivative BI292 and preparation method and application thereof Download PDFInfo
- Publication number
- CN112920242B CN112920242B CN202110118455.3A CN202110118455A CN112920242B CN 112920242 B CN112920242 B CN 112920242B CN 202110118455 A CN202110118455 A CN 202110118455A CN 112920242 B CN112920242 B CN 112920242B
- Authority
- CN
- China
- Prior art keywords
- compound
- benzimidazole derivative
- tetrahydrofuran
- hydroxymethyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- 150000001556 benzimidazoles Chemical class 0.000 claims abstract description 22
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims abstract description 14
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract description 9
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 16
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 229910001868 water Inorganic materials 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- -1 (4-methylbenzoyl) oxy Chemical group 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000002953 preparative HPLC Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- NKWCGTOZTHZDHB-UHFFFAOYSA-N 1h-imidazol-1-ium-4-carboxylate Chemical compound OC(=O)C1=CNC=N1 NKWCGTOZTHZDHB-UHFFFAOYSA-N 0.000 claims description 6
- NQUVCRCCRXRJCK-UHFFFAOYSA-N 4-methylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1 NQUVCRCCRXRJCK-UHFFFAOYSA-N 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000012044 organic layer Substances 0.000 claims description 6
- 239000003208 petroleum Substances 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 claims description 6
- UKCUMUNHQHKHFT-UHFFFAOYSA-N butane-1,1,3-triol Chemical compound CC(O)CC(O)O UKCUMUNHQHKHFT-UHFFFAOYSA-N 0.000 claims description 5
- 239000012043 crude product Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- VVQNAFBGAWCMLU-UHFFFAOYSA-N 1h-benzimidazole-4-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1N=CN2 VVQNAFBGAWCMLU-UHFFFAOYSA-N 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 4
- 239000012346 acetyl chloride Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004237 preparative chromatography Methods 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 7
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- 239000012453 solvate Substances 0.000 abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 9
- 229940126214 compound 3 Drugs 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 229940009456 adriamycin Drugs 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000030224 brain astrocytoma Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a benzimidazole derivative BI292 and a preparation method thereof, wherein the chemical name of the benzimidazole derivative BI292 is 1- [ (2R,4S,5R) -4-hydroxy-5- (hydroxymethyl) tetrahydrofuran-2-yl ] -1H-benzo [ d ] imidazole-4-carboxylic acid methyl ester. The benzimidazole derivative and the pharmaceutically acceptable salt, solvate and hydrate thereof have excellent antitumor in-vitro and in-vivo activities on MCF-7, SK-BR-3, HCT116, U-118MG, U-87MG and MDA-MB-468, and have good application prospects in preparation of antitumor drugs.
Description
Technical Field
The invention belongs to the field of biomedicine, and particularly relates to a benzimidazole derivative BI292 as well as a preparation method and application thereof.
Background
Malignant tumor is a common disease and frequently encountered disease seriously threatening human health, and the death rate of the tumor in China has increased 29.42% in recent 20 years. In the middle-aged and senior population, between the ages of 35 and 59, tumors have been the first cause of death of various types. And (3) displaying data: the disease rate of tumors in China is about 200/10 ten thousands of people, more than 220 thousands of new cases are generated every year, and more than 600 thousands of patients are treated. The tumor treatment method includes operation treatment, radiotherapy and chemotherapy. Currently, chemotherapy remains the primary means of clinical treatment of tumors. The search for anti-tumor drugs is one of the hot spots in the research of new drugs. In recent years, benzimidazole compounds have attracted much attention because of their excellent biological activity, and have become a focus of research for researchers in biology and chemistry. The indications include: peptic ulcer, parasitic infection, bacterial infection, viral infection, tumor, etc., and particularly, has the effect of selectively inhibiting glioblastoma and other tumors. The inventor unexpectedly finds that methyl 1- [ (2R,4S,5R) -4-hydroxy-5- (hydroxymethyl) tetrahydrofuran-2-yl ] -1H-benzo [ d ] imidazole-4-carboxylate has certain antitumor activity, and proposes the invention related to methyl 1- [ (2R,4S,5R) -4-hydroxy-5- (hydroxymethyl) tetrahydrofuran-2-yl ] -1H-benzo [ d ] imidazole-4-carboxylate or a pharmaceutically acceptable salt, solvate or prodrug or stereoisomer or tautomer or metabolite of the compound.
Disclosure of Invention
The purpose of the invention is as follows: in order to solve the problems in the prior art, the invention provides a benzimidazole derivative BI292 which is chemically named as 1- [ (2R,4S,5R) -4-hydroxy-5- (hydroxymethyl) tetrahydrofuran-2-yl ] -1H-benzo [ d ] imidazole-4-carboxylic acid methyl ester and has inhibitory activity on proliferation of MCF-7, SK-BR-3, HCT116, U-118MG, U-87MG and MDA-MB-468 six tumor cells.
The technical scheme is as follows: in order to achieve the technical purpose, the invention provides a benzimidazole derivative BI292, which is chemically named as 1- [ (2R,4S,5R) -4-hydroxy-5- (hydroxymethyl) tetrahydrofuran-2-yl ] -1H-benzo [ d ] imidazole-4-carboxylic acid methyl ester and has the following structural formula:
the invention further provides a preparation method of the benzimidazole derivative BI292, which comprises the following steps:
s1: under the protection of nitrogen, methanol solution, 5- (hydroxymethyl) oxapentane-2, 4-diol and CH3COCl is mixed and stirred for 20-45 minutes, pyridine is diluted and concentrated, Py, 4-dimethylaminopyridine and 4-methylbenzoyl chloride are added, stirring is carried out for 1-1.5 hours at the temperature of 0 ℃, and stirring is carried out at the room temperature overnight; adding water to stop the reaction, extracting with dichloromethane, combining organic layers, and sequentially using saturated NaHCO3Solution, 15% H2SO4Washing, drying over anhydrous sodium sulfate, concentrating in vacuo and triturating with ether, filtering off the solid, concentrating the filtrate in vacuo, adding ether acetic acid to the resulting residue at 0 deg.C, introducing hydrochloric acid gas for 10-15 minutes, collecting the solid by filtration and washing with ether/petroleum ether to give compound (1), i.e. (2R,3S,5S) -5-chloro-2- { [ (4-methylbenzoyl) oxy)]Methyl } tetrahydrofuran-3-yl-4-benzoic acid methyl ester.
S2：1H-1, 3-benzodiazole-4-carboxylic ester and CH3CN and BSA are put into a round-bottom flask and stirred for 15 to 20 minutes at the temperature of 80 ℃; to CH at room temperature3CN TMSOTf and compound (1) are added; mixing the above solutions at 85 deg.C, stirring for 2.5-3h, cooling to room temperature, diluting with water, extracting with ethyl acetate for several times, combining organic layers, drying over anhydrous sodium sulfate, vacuum concentrating, eluting the obtained residue with ethyl acetate/petroleum ether on silica gel column, and purifying the crude product by flash preparative high performance liquid chromatography to obtain compound (2), i.e. methyl- { (2R,4S,5R) -4- [ (4-methylbenzoyl) oxy ] carbonyl]-5- { [ (4-methylbenzoyl) oxy]Methyl } tetrahydrofuran-2-yl } -1H-benzo [ d]Imidazole-4-carboxylic acid esters;
s3: placing compound (2) and methanol, tetrahydrofuran, sodium methoxide in a round bottom flask, stirring at room temperature for 1.5-2H, adjusting the solution to neutrality with hydrochloric acid, concentrating the reaction mixture in vacuum, and purifying the obtained residue by flash preparative high performance liquid chromatography to obtain compound (3), i.e. methyl 1- [ (2R,4S,5R) -4-hydroxy-5- (hydroxymethyl) tetrahydrofuran-2-yl ] -1H-benzo [ d ] imidazole-4-carboxylate.
Preferably, in step S1, the methanol solution, 5- (hydroxymethyl) oxapentane-2, 4-diol, and CH3The dosage ratio of COCl, pyridine, 4-dimethylaminopyridine and 4-methylbenzoyl chloride is 60-120 mL: 6-12 g: 0.1-0.5 mL: 20-60 mL: 0.5-5 g: 10-30 mL.
In step S2, 1H-1, 3-benzodiazole-4-carboxylate, CH3CN, BSA, TMSOTf and compound (1) were used in the following ratios: 0.5-5 g: 60-100 mL: 0.5-5 g: 0.5-5 g: 3-10 g, the reaction temperature is 60-100 ℃, and the reaction time is 90-180 minutes. The mobile phase gradient elution conditions for purifying the crude product by flash preparative high performance liquid chromatography are H2O(0.1％HCOOH)：CH3CN＝1:10～10:1。
In step S3, the compound (2), methanol, THF, and sodium methoxide are used in the following amounts: 1-5 g: 60-100 mL: 60-100 mL: 0.1-0.5 g, and the mobile phase gradient elution conditions for purification by preparative chromatography are as follows: h2O(0.1％NH4HCO3)：CH3CN＝20:1～1:5。
The invention further provides application of the benzimidazole derivative in preparing an antitumor agent.
The present invention also provides a pharmaceutical composition comprising a compound as set forth in claim 1 above and a pharmaceutically acceptable carrier.
More particularly, the invention provides the use of the compound or the pharmaceutical composition in the preparation of medicaments.
Meanwhile, the invention also provides application of the benzimidazole derivative BI292 or pharmaceutically acceptable salt, solvate or prodrug or stereoisomer or tautomer or metabolite of the compound in preparation of antitumor agents.
Finally, the invention provides the application of the benzimidazole derivative BI292 or the pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, tautomer or metabolite of the compound in preparing the medicine for treating tumors by combining with one or more anticancer agents.
Has the advantages that: the invention discloses a benzimidazole derivative BI292, which is used for evaluating the proliferation activities of 6 tumor cells of MCF-7, SK-BR-3, HCT116, U-118MG, U-87MG and MDA-MB-468 inhibition by adopting an MTT method, and calculating the IC for inhibiting the proliferation of the six tumor cells50The value and the result show that the prepared benzimidazole derivative BI292 has an inhibition effect on the tumor cells and can be used for preparing an anti-tumor preparation.
Drawings
Fig. 1 is a scheme for the synthesis of benzimidazole derivatives, wherein: i) acetyl chloride, methanol, pyridine, 4-dimethylaminopyridine, 4-methylbenzoyl chloride; ii) BSA, TMSOTf, acetonitrile; iii) methanol, sodium methoxide.
Detailed Description
To further illustrate the invention, a series of examples are given below. These examples are purely illustrative and are intended to be a detailed description of the invention only and should not be taken as limiting the invention.
EXAMPLE 1 preparation of methyl (2R,3S,5S) -5-chloro-2- { [ (4-methylbenzoyl) oxy ] methyl } tetrahydrofuran-3-yl-4-benzoate (Compound 1)
To a 250mL round bottom flask maintained under nitrogen at room temperature were added 100mL of methanol solution, 6.8g of 5- (hydroxymethyl) oxapentane-2, 4-diol, and 0.4mL of CH3COCl. The mixture was stirred for 45 minutes, diluted with 10mL pyridine and concentrated to a yellow oil. 20mL of Py, 0.5g of 4-dimethylaminopyridine and 14mL of 4-methylbenzoyl chloride were added, and the mixture was stirred at 0 ℃ for 1.5 hours and at room temperature overnight. The reaction was then quenched by the addition of 100mL of water and extracted several times with 100mL of dichloromethane. The organic layers were combined and washed with 100mL saturated NaHCO3Solution, 100mL 15% H2SO4Washed several times, dried over anhydrous sodium sulfate, concentrated in vacuo and triturated with 20mL of diethyl ether. The resulting solid was filtered off and the filtrate was concentrated in vacuo. The residue was added with 100mL of diethyl ether and 50mL of acetic acid at 0 ℃. Hydrochloric acid gas was introduced into the above solution for 10 minutes. The solid was collected by filtration and washed with 100mL diethyl ether/petroleum ether (1: 1). 12.5g (yield 63%) of Compound 1 are obtained as a white solid.
Compound 1 was characterized by LC-MS as follows:
LC-MS:(ES,m/z):353[M-Cl-]+
EXAMPLE 2 preparation of methyl- { (2R,4S,5R) -4- [ (4-methylbenzoyl) oxy ] -5- { [ (4-methylbenzoyl) oxy ] methyl } tetrahydrofuran-2-yl } -1H-benzo [ d ] imidazole-4-carboxylate (Compound 2)
2.1g of 1H-1, 3-benzodiazole-4-carboxylate, 80mL of CH3CN was charged into a 250mL round-bottom flask, and 2.68g BSA was added at 80 ℃ and stirred for 15 minutes. Followed by addition of the solution in 10mLCH at room temperature3CN 3.97g of TMSOTf and 6.94g of Compound (1). The above solutions were mixed and stirred at 85 ℃ for 2.5 h. Cooled to room temperature, diluted with 100mL of water and extracted several times with 100mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was eluted with ethyl acetate/petroleum ether (10:1) on a silica gel column. The crude product was purified by flash preparative high performance liquid chromatography under the following conditions: c18Mobile phase, H2O(0.1％HCOOH)：CH3CN is 3:1, inDetector, UV254nm, within 25 minutes. 2.4g (38% yield) of Compound 2 are obtained as a pale yellow solid.
Compound 2 was characterized by LC-MS as follows:
LC-MS:(ES,m/z):529.1[M+H]+
H-NMR:(300MHz,DMSO-d6,ppm):δ8.623(s,1H),7.93-8.04(m,3H),7.85-7.79(m,3H),7.40-7.19(m,5H),6.66(dd,J＝6Hz,J＝1.8Hz,1H),5.76(d,J＝6.3Hz,1H),4.65-4.55(m,3H),3.95(s,3H),3.16-3.06(m,1H),2.86-2.74(m,1H),2.42(s,3H),2.38(s,3H).
EXAMPLE 3 preparation of methyl 1- [ (2R,4S,5R) -4-hydroxy-5- (hydroxymethyl) tetrahydrofuran-2-yl ] -1H-benzo [ d ] imidazole-4-carboxylate (Compound 3)
After 2.4g of compound 2 and 80mL of methanol, 80mL of THF and 245mg of sodium methoxide have been stirred at room temperature for 1.5h, the solution is adjusted to neutrality with hydrochloric acid. The reaction mixture was concentrated under vacuum. The resulting residue was purified by flash preparative high performance liquid chromatography under the following conditions: chromatography column, C18(ii) a Mobile phase, water (0.1% NH)4HCO3)：CH3CN 20:1, added to water (0.1% NH)4HCO3)：CH3CN 1:2 in 20 minutes; detector, UV254 nm. 0.6498g (yield 49%) of compound 3 were obtained as a white solid.
ESI-MS and the like were performed on the prepared Compound 3, and the results were as follows:
LC-MS:(ES,m/z):293.20[M+H]+
H-NMR:(300MHz,DMSO-d6,ppm):δ8.59(s,1H),8.01(d,J＝7.5Hz,1H),7.79(d,J＝6.9Hz,1H),7.36(t,J＝7.8Hz,1H),6.42(t,J＝6.8Hz,1H),5.36(s,1H),4.99(s,1H),4.42-4.40(m,1H),3.89(s,4H),3.56(s,2H),2.63-2.57(m,1H),2.37-2.30(m,1H).
experimental example 4 evaluation of antitumor cell proliferating activity by Compound 3.
(1) And (3) testing a sample:
the compounds 3 of the invention were all formulated to the desired concentration in media containing 0.1% DMSO.
(2) Cell lines:
MCF-7 (human breast cancer cells, ATCC: HTB-22), SK-BR-3 (human breast cancer cells, ATCC: HTB-30), HCT116 (human colon cancer cells, ATCC: CCL-247), U-118MG (human brain astrocytoma, ATCC: HTB-15), U-87MG (human brain astrocytoma, ATCC: HTB-14), and MDA-MB-468 (human breast cancer cells, ATCC: HTB-132)6 tumor cells were purchased from American Standard culture Collection (ATCC).
(3) Main instruments and materials
Ultra-pure water instrument: MILLIPORE Direct-Q3;
an autoclave: HVE-50, Hirayama corporation;
digital display constant temperature water bath: HH-4, Kyowa electric appliances, Inc.;
an ultra-clean bench: VS-1300-U clean bench, Suzhou Antai air technology, Inc.;
a cell incubator: HF151UVCO2 incubator, shanghai li cheng;
low-temperature centrifuger: shanghai' an pavilion scientific instrument factory
An enzyme-labeling instrument: ELx800 Biotek Inc
A flat plate oscillator: ZD-9556, Taicang scientific and educational facilities;
96-well cell culture plate, 25cm2Culture bottles: corning Costar corporation;
2mL of frozen tubes: corning Costar corporation;
(4) primary reagent
RPMI-1640 medium: gibco corporation;
DMEM medium: gibco corporation;
l-15 Medium: gibco corporation;
McCoy's 5A medium: gibco corporation;
MEM medium: gibco corporation;
PBS buffer: gibco corporation;
fetal bovine serum: gibco corporation;
0.25% pancreatin solution: hyclone company;
MTT (thiazolidine blue): sigma, dissolving in PBS solution to make 5mg/mL solution, filtering, sterilizing, and storing in dark place;
doxorubicin (ADR): beijing Huafeng Union technologies, Inc.
DMSO, DMSO: dimethyl sulfoxide, Sigma corporation;
(5) test method
The MCF-7 and U-118MG cells adopt DMEM culture medium, the U-87MG cells adopt MEM culture medium, the MDA-MB-468 cells adopt L-15 culture medium, the HCT116 cells adopt McCoy's 5A culture medium, and other cells adopt RPMI-1640 culture medium. The culture medium contains 10% of extinguishant fetal calf serum and 80 U.mL-1Penicillin and 0.08 mg/mL-1Streptomycin.
MCF-7, SK-BR-3, HCT116, U-118MG, U-87MG and MDA-MB-468 cells in logarithmic growth phase with good growth state are divided into 1 × 104The cells were plated at a density of 100. mu.l/well in 96-well plates. Placing at 37 ℃ and 5% CO2Culturing in an incubator for 12 hours to adhere to the wall. Adding a compound 3 dissolved in a culture medium to be detected and subjected to sterilization treatment into a drug-added cell hole according to a preset concentration gradient, wherein each hole is 200 mu l, adding an equal volume of the culture medium into a blank cell hole, adding an equal volume of Adriamycin (ADR) dissolved in the culture medium into a control cell hole according to a preset concentration gradient, and paralleling 6 holes. At 37 deg.C, 5% CO2After 48 hours of incubation in an incubator, 10. mu.l of 5mg/mL MTT solution was added to each well, and the mixture was further incubated at 37 ℃ with 5% CO2The culture was carried out in an incubator for 4 hours. The supernatant was carefully aspirated, 150. mu.l of DMSO was added to each well to dissolve the purple residue (formazan), the plate was shaken for 10 minutes to dissolve the precipitate completely, and the O.D. value (absorbance) was measured on a microplate reader at a wavelength of 570 nm.
The inhibition rate of the sample on tumor cells at each sample concentration was calculated according to the formula "relative survival rate ═ D blank containing drug (D)/(D control-D blank) × 100%".
The experiment was repeated 3 times in parallel and the inhibition rate was plotted against the compound concentration to calculate the IC of compound 3 of the invention50(median effective inhibitory concentration) value. While doxorubicin (ADR) was used as a positive control drug.
(6) Results of the experiment
TABLE 1 Compound 3BI292 antitumor cell proliferation Activity (IC)50±SDμM)
As shown in Table 1, the test results of the compound 3 on the proliferation activity of the tumor cells are shown, and the results show that the prepared benzimidazole derivative has an inhibition effect on the tumor cells and can be used for preparing an anti-tumor preparation.
Claims (9)
1. A benzimidazole derivative BI292, its chemical name is 1- [ (2R,4S,5R) -4-hydroxy-5- (hydroxymethyl) tetrahydrofuran-2-yl ] -1H-benzo [ d ] imidazole-4-carboxylic acid methyl ester, and its pharmaceutically acceptable salt.
2. The process for preparing the benzimidazole derivative BI292 according to claim 1, comprising the steps of:
s1: under the protection of nitrogen, methanol solution, 5- (hydroxymethyl) oxapentane-2, 4-diol and CH3COCl is mixed and stirred for 20-45 minutes, pyridine is diluted and concentrated, Py, 4-dimethylaminopyridine and 4-methylbenzoyl chloride are added, stirring is carried out for 1-1.5 hours at the temperature of 0 ℃, and stirring is carried out at the room temperature overnight; adding water to stop the reaction, extracting with dichloromethane, combining organic layers, and sequentially using saturated NaHCO3Solution, 15% H2SO4Washing, drying over anhydrous sodium sulfate, concentrating in vacuo and triturating with ether, filtering off the solid, concentrating the filtrate in vacuo, adding ether acetic acid to the resulting residue at 0 deg.C, introducing hydrochloric acid gas for 10-15 minutes, collecting the solid by filtration and washing with ether/petroleum ether to give compound (1), i.e. (2R,3S,5S) -5-chloro-2- { [ (4-methylbenzoyl) oxy)]Methyl } tetrahydrofuran-3-yl-4-benzoic acid methyl ester;
s2: 1H-1, 3-benzodiazole-4-carboxylic ester and CH3CN and BSA are put into a round-bottom flask and stirred for 15 to 20 minutes at the temperature of 80 ℃; to CH at room temperature3CN TMSOTf and compound (1) are added; mixing the above solutions at 85 deg.C, stirring for 2.5-3h, cooling to room temperature, diluting with water, extracting with ethyl acetate for several times, mixing organic layers, drying with anhydrous sodium sulfate, vacuum concentrating, eluting the obtained residue with ethyl acetate/petroleum ether on silica gel column, and purifying with silica gel columnFlash preparative high performance liquid chromatography purification of the crude product to yield compound (2), methyl- { (2R,4S,5R) -4- [ (4-methylbenzoyl) oxy]-5- { [ (4-methylbenzoyl) oxy]Methyl } tetrahydrofuran-2-yl } -1H-benzo [ d]Imidazole-4-carboxylic acid esters;
s3: placing compound (2) and methanol, tetrahydrofuran, sodium methoxide in a round bottom flask, stirring at room temperature for 1.5-2H, adjusting the solution to neutrality with hydrochloric acid, concentrating the reaction mixture in vacuum, and purifying the obtained residue by flash preparative high performance liquid chromatography to obtain compound (3), i.e. methyl 1- [ (2R,4S,5R) -4-hydroxy-5- (hydroxymethyl) tetrahydrofuran-2-yl ] -1H-benzo [ d ] imidazole-4-carboxylate.
3. The method of claim 2, wherein in step S1, the mixture of the benzimidazole derivative BI292 comprises methanol solution, 5- (hydroxymethyl) oxapentane-2, 4-diol, and CH3The dosage ratio of COCl, pyridine, 4-dimethylaminopyridine and 4-methylbenzoyl chloride is 60-120 mL: 6-12 g: 0.1-0.5 mL: 20-60 mL: 0.5-5 g: 10-30 mL.
4. The method of claim 2, wherein in step S2, 1H-1, 3-benzodiazole-4-carboxylate, CH3CN, BSA, TMSOTf and compound (1) were used in the following ratios: 0.5-5 g: 60-100 mL: 0.5-5 g: 0.5-5 g: 3-10 g, and the mobile phase gradient elution conditions for purifying the crude product by adopting the rapid preparative high performance liquid chromatography are as follows: h containing 0.1% HCOOH2O：CH3CN=3:1。
5. The method for preparing the benzimidazole derivative BI292 according to claim 2, wherein the compound (2), methanol, THF, and sodium methoxide are used in the following ratio in step S3: 1-5 g: 60-100 mL: 60-100 mL: 0.1-0.5 g, and the mobile phase gradient elution conditions for purification by preparative chromatography are as follows: in 20 minutes, the mobile phase is composed of a mixture containing 0.1% NH4HCO3H of (A) to (B)2O：CH3CN =20:1 increase to 0.1% NH4HCO3H of (A) to (B)2O：CH3CN=1:2。
6. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
7. Use of a compound of claim 1, or a pharmaceutical composition of claim 6, in the manufacture of a medicament.
8. Use of the benzimidazole derivative BI292 or a pharmaceutically acceptable salt thereof as claimed in claim 1 for the preparation of an antitumor agent.
9. Use of the benzimidazole derivative BI292 or a pharmaceutically acceptable salt of said compound of claim 1 in combination with one or more anticancer agents for the preparation of a medicament for the treatment of tumors.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110118455.3A CN112920242B (en) | 2021-01-28 | 2021-01-28 | Benzimidazole derivative BI292 and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110118455.3A CN112920242B (en) | 2021-01-28 | 2021-01-28 | Benzimidazole derivative BI292 and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112920242A CN112920242A (en) | 2021-06-08 |
| CN112920242B true CN112920242B (en) | 2021-12-21 |
Family
ID=76168006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110118455.3A Active CN112920242B (en) | 2021-01-28 | 2021-01-28 | Benzimidazole derivative BI292 and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112920242B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003051898A1 (en) * | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Unusual nucleoside libraries, compounds, and preferred uses as antiviral and anticancer agents |
-
2021
- 2021-01-28 CN CN202110118455.3A patent/CN112920242B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003051898A1 (en) * | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Unusual nucleoside libraries, compounds, and preferred uses as antiviral and anticancer agents |
Non-Patent Citations (2)
| Title |
|---|
| Covalently cross-linked Watson-Crick base pair models.Part 2;Qiu, Y.-L.等;《Tetrahedron Letters》;20001231;第41卷(第49期);第9425-9429页 * |
| Synthesis of lin-benzoinosine, lin-benzoxanthosine,and lin-benzoguanosine;Keyser, Gene E.等;《Journal of Organic Chemistry》;19791231;第44卷(第17期);第2989-2994页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112920242A (en) | 2021-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116143842A (en) | Cyclometallic iridium complexes of oxidized isoaporphyl alkaloids and N-heterocyclic carbene, and their synthesis methods and applications | |
| DE69127691T2 (en) | BE-13793C DERIVATIVE WITH ANTITUARY EFFECT | |
| CN112358518B (en) | Benzimidazole derivative BI277 and preparation method and application thereof | |
| CN112920242B (en) | Benzimidazole derivative BI292 and preparation method and application thereof | |
| US20160022668A1 (en) | Application of cinchona alkaloid derivatives as cytotoxic compounds | |
| CN110981881A (en) | Chelandine nitric oxide donor derivative and preparation method and use thereof | |
| CN112920241B (en) | Benzimidazole derivative BI308 and preparation method and application thereof | |
| CA2888015C (en) | 2',5'-dideoxy-5-fluorouridine derivatives having cytotoxic activity, a process for the manufacture thereof and application thereof | |
| CN112250725B (en) | Benzimidazole derivative BI345 and preparation method and application thereof | |
| CN112358517B (en) | Benzimidazole derivative BI305 and preparation method and application thereof | |
| CN112812145B (en) | Benzimidazole derivative BI293 and preparation method and application thereof | |
| CN112375112B (en) | Benzimidazole derivative BI361 and preparation method and application thereof | |
| CN112300235B (en) | Benzimidazole derivative BI321 and preparation method and application thereof | |
| CN108191866A (en) | A kind of ADT-OH classes H2S donors and rutaecarpin splicing object and its preparation method and application | |
| CN105541872B (en) | A kind of adjacent naphthoquinone derivatives and preparation method thereof and medical usage | |
| CN111196791B (en) | Chiral gamma-butyrolactone derivative and synthesis method and application thereof | |
| CN110759961B (en) | A class of ursolic acid indolequinone amide derivatives and their preparation method and application | |
| CA2887039C (en) | 2',3'-dideoxy-5-fluorouridine derivatives, a process for the manufacture thereof and application thereof | |
| CN116925029B (en) | Coumarin-piperazine-dithiocarbamate hybrid and preparation method and application thereof | |
| CN114957340B (en) | Preparation method and application of binuclear iridium complex for inducing iron death | |
| CN116925018B (en) | Rhein-piperazine-furanone hybrid and its preparation method and application | |
| CN110183471B (en) | A kind of piperazine derivatives and preparation method and application | |
| CN115594715B (en) | Targeted mitochondria chalcone derivative and application thereof | |
| CN113801107B (en) | Preparation and application of a naringenin derivative with antitumor activity and its Ni(II) complex | |
| CN117185992A (en) | Preparation method and application of benzamide derivative containing aryloxy bipyridine methyl thiourea unit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |